These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33154299)

  • 21. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
    Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
    Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic and prognostic value of plasma cell-free DNA combined with VEGF-C in laryngeal squamous cell carcinoma.
    Huang Q; Ji M; Li F; Li Y; Zhou X; Hsueh CY; Zhou L
    Mol Cell Probes; 2023 Feb; 67():101895. PubMed ID: 36682577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum vascular endothelial growth factor-A (VEGF-A) as a biomarker in squamous cell carcinoma of head and neck patients undergoing chemoradiotherapy.
    Srivastava VK; Gara RK; Rastogi N; Mishra DP; Ahmed MK; Gupta S; Goel MM; Bhatt ML
    Asian Pac J Cancer Prev; 2014; 15(7):3261-5. PubMed ID: 24815480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of concomitant chemoradiation in locally advanced head and neck cancers.
    Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA
    Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating extracellular vesicle-associated TGFβ3 modulates response to cytotoxic therapy in head and neck squamous cell carcinoma.
    Rodrigues-Junior DM; Tan SS; Lim SK; Leong HS; Melendez ME; Ramos CRN; Viana LS; Tan DSW; Carvalho AL; Iyer NG; Vettore AL
    Carcinogenesis; 2019 Dec; 40(12):1452-1461. PubMed ID: 31436806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
    Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
    Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal cell-free DNA characterization by low-coverage whole-genome sequencing in patients undergoing high-dose radiotherapy.
    Balázs Z; Balermpas P; Ivanković I; Willmann J; Gitchev T; Bryant A; Guckenberger M; Krauthammer M; Andratschke N
    Radiother Oncol; 2024 Aug; 197():110364. PubMed ID: 38834154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
    Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
    Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
    BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.
    Patimarattananan T; Nongnuch A; Pattaranutaporn P; Unwanatham N; Jiarpinitnun C; Ngamphaiboon N
    Support Care Cancer; 2021 Feb; 29(2):877-887. PubMed ID: 32524284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma.
    Payne K; Spruce R; Beggs A; Sharma N; Kong A; Martin T; Parmar S; Praveen P; Nankivell P; Mehanna H
    Head Neck; 2018 Jul; 40(7):1598-1604. PubMed ID: 29542214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.
    Douvdevani A; Bernstein-Molho R; Asraf K; Doolman R; Laitman Y; Friedman E
    Cancer Biomark; 2020; 28(3):269-273. PubMed ID: 32280079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study.
    Wang K; Yi J; Huang X; Qu Y; Luo J; Xiao J; Zhang S; Tang Y; Liu W; Xu G; Gao L; Xu Z; Liu S; Wang X
    Radiat Oncol; 2019 Dec; 14(1):225. PubMed ID: 31831042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC).
    Economopoulou P; Koutsodontis G; Strati A; Kirodimos E; Giotakis E; Maragoudakis P; Prikas C; Papadimitriou N; Perisanidis C; Gagari E; Kotsantis I; Vagia E; Anastasiou M; Gkotzamanidou M; Kavourakis G; Lianidou E; Psyrri A
    Oral Oncol; 2019 Jul; 94():93-100. PubMed ID: 31178219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma.
    Park S; Lee EJ; Rim CH; Seong J
    Yonsei Med J; 2018 Jun; 59(4):470-479. PubMed ID: 29749129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
    Schüttrumpf L; Marschner S; Scheu K; Hess J; Rietzler S; Walch A; Baumeister P; Kirchner T; Ganswindt U; Zitzelsberger H; Belka C; Maihoefer C
    Radiat Oncol; 2020 Jan; 15(1):7. PubMed ID: 31906998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased Plasma Circulating Cell-Free DNA Could Be a Potential Marker for Oral Cancer.
    Lin LH; Chang KW; Kao SY; Cheng HW; Liu CJ
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30352977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatic mutations in tumor and plasma of locoregional recurrent and/or metastatic head and neck cancer using a next-generation sequencing panel: A preliminary study.
    Rapado-González Ó; Brea-Iglesias J; Rodríguez-Casanova A; Bao-Caamano A; López-Cedrún JL; Triana-Martínez G; Díaz-Peña R; Santos MA; López-López R; Muinelo-Romay L; Martínez-Fernández M; Díaz-Lagares Á; Suárez-Cunqueiro MM
    Cancer Med; 2023 Mar; 12(6):6615-6622. PubMed ID: 36420687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
    Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
    BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?
    Haehl E; Rühle A; David H; Kalckreuth T; Sprave T; Stoian R; Becker C; Knopf A; Grosu AL; Nicolay NH
    Radiat Oncol; 2020 Feb; 15(1):31. PubMed ID: 32019576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.